Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon

• Published in: Journal of global oncology Vol. 5; no. 5; pp. 1 - 7
• Main Authors: Elias, Fadia, Gebran, Anthony, Said, Christina, Beker, Russell V, Ammar, Walid
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 01-06-2019
• Subjects: Antineoplastic Agents - economics; Antineoplastic Agents - therapeutic use; Dasatinib - economics; Dasatinib - therapeutic use; Disease-Free Survival; Economics; Female; Health Expenditures; Hematologic Malignancies: Leukemias; Humans; Imatinib Mesylate - economics; Imatinib Mesylate - therapeutic use; Lebanon; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - economics; Lost to Follow-Up; Protein Kinase Inhibitors - economics; Protein Kinase Inhibitors - therapeutic use; Public Health; Pyrimidines - economics; Pyrimidines - therapeutic use; Remission Induction; Special; Treatment Outcome; Lebanon
• ISSN: 2378-9506; 2378-9506
• DOI: 10.1200/JGO.19.00012

Chronic myeloid leukemia (CML) ranks second in terms of disease-related health care expenditures at the Lebanese Ministry of Public Health (MoPH) after breast cancer. With the introduction of tyrosine kinase inhibitors (TKIs), survival of patients with CML has dramatically improved and approached that of the normal population. In recent years, several studies demonstrated that patients who achieve a deep molecular response while receiving TKI therapy could safely attempt treatment-free remission (TFR), the new treatment goal in patients with CML. The objective is to estimate the budget impact of TFR at the MoPH.
Analyses were done on 162 patients with CML receiving imatinib, nilotinib, or dasatinib, as first-line or second-line therapy, over a 4-year time horizon using MoPH drug pricing. The model assumed that patients could attempt TFR after 36 months of TKI therapy, where the last 24 months were at stable molecular response as per MoPH and National Comprehensive Cancer Network guidelines. Duration of TFR was based on European Stop Kinase Inhibitor treatment-free survival curve.
Out of the 162 patients, 83 were eligible to attempt TFR, 36 patients were not eligible, 32 patients were lost to follow-up, two patients died as a result of CML progression, and five died as a result of other causes. The total cost of CML treatment with TFR from the time of analysis and over 4 years can be reduced by more than 7 million US dollars (57%).
The model can be used to inform health care decision makers on the importance of TFR and the potential savings.